BIOMAT Database Logo BIOMAT Database Logo

Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study. 1997

A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
Mental Health Research Institute, University of Michigan, Ann Arbor 48109-0720, USA.

Structural elements of the rat mu-opioid receptor important in ligand receptor binding and selectivity were examined using a site-directed mutagenesis approach. Five single amino acid mutations were made, three that altered conserved residues in the mu, delta, and kappa receptors (Asn150 to Ala, His297 to Ala, and Tyr326 to Phe) and two designed to test for mu/delta selectivity (Ile196 to Val and Val202 to Ile). Mutation of His297 in transmembrane domain 6 (TM6) resulted in no detectable binding with [3H]DAMGO (3H-labeled D-Ala2, N-Me-Phe4, Gly-ol5-enkephalin), [3H]bremazocine, or [3H]ethylketocyclazocine. Mutation of Asn150 in TM3 produces a three- to 20-fold increase in affinity for the opioid agonists morphine, DAMGO, fentanyl, beta-endorphin1-31, JOM-13, deltorphin II, dynorphin1-13, and U50,488, with no change in the binding of antagonists such as naloxone, naltrexone, naltrindole, and nor-binaltorphamine. In contrast, the Tyr326 mutation in TM7 resulted in a decreased affinity for a wide spectrum of mu, delta, and kappa agonists and antagonists. Altering Val202 to Ile in TM4 produced no change on ligand affinity, but Ile196 to Val resulted in a four- to fivefold decreased affinity for the mu agonists morphine and DAMGO, with no change in the binding affinities of kappa and delta ligands.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004350 Drug Residues Drugs and their metabolites which are found in the edible tissues and milk of animals after their medication with specific drugs. This term can also apply to drugs found in adipose tissue of humans after drug treatment. Drug Residue,Residue, Drug,Residues, Drug
D004745 Enkephalins One of the three major families of endogenous opioid peptides. The enkephalins are pentapeptides that are widespread in the central and peripheral nervous systems and in the adrenal medulla. Enkephalin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D016314 Ethylketocyclazocine A kappa opioid receptor agonist. The compound has analgesic action and shows positive inotropic effects on the electrically stimulated left atrium. It also affects various types of behavior in mammals such as locomotion, rearing, and grooming. Ethylketazocine,Ethylketocyclazocine Methanesulfonate,Win-35197-2,Win 35197 2,Win351972

Related Publications

A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
Creating a functional opioid alkaloid binding site in the orphanin FQ receptor through site-directed mutagenesis.
April 1998, Molecular pharmacology,
A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
Functional significance of cysteine residues in the delta opioid receptor studied by site-directed mutagenesis.
March 1998, Canadian journal of physiology and pharmacology,
A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
Site-directed mutagenesis of two aromatic residues lining the active site pocket of the yeast Ltp1.
May 2007, Biochimica et biophysica acta,
A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling.
February 2003, The Journal of biological chemistry,
A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis.
January 1989, Proceedings of the National Academy of Sciences of the United States of America,
A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
Defining HIV-1 Vif residues that interact with CBFβ by site-directed mutagenesis.
January 2014, Virology,
A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
Cel48A from Thermobifida fusca: structure and site directed mutagenesis of key residues.
April 2014, Biotechnology and bioengineering,
A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
The ligand binding site of the neurokinin 2 receptor. Site-directed mutagenesis and identification of neurokinin A binding residues in the human neurokinin 2 receptor.
November 1994, The Journal of biological chemistry,
A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
Site-directed random mutagenesis of AMP-binding residues in adenylate kinase.
November 1993, Journal of biochemistry,
A Mansour, and L P Taylor, and J L Fine, and R C Thompson, and M T Hoversten, and H I Mosberg, and S J Watson, and H Akil
Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site.
September 1999, European journal of pharmacology,
Copied contents to your clipboard!